Dr Reddys Laboratories
- Market Cap
- ₹1,16,037 Cr
- P/E
- 41.44
Key Fundamentals
LargecapPharmaceuticals & BiotechnologyHealthcarePrice-based figures as of · EPS basis: Consolidated · TTM
- ROCE
- 13.00%
- Debt to Equity
- 0.19
- EPS (TTM)
- ₹33.55
- Book Value
- ₹464.94
- Market Cap
- ₹1,16,037 Cr
- P/E (TTM)
- 41.44
- P/B
- 2.99
- ROE
- 11.20%
- Dividend Yield
- 0.57%
- EBITDA
- ₹7,812 Cr
- 52W High
- ₹1,414.90
- 52W Low
- ₹1,101.00
- Day Range
- ₹1,384.80 – ₹1,400.00
- Volume
- 8,30,660
Peer Comparison
Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals
| 1,884.90 | 41.25 | 4,52,251 | 5.07 | 0.85% | 16.00% | 20.50% | 61,631 | 10,987 | |
| 11,180.50 | 88.26 | 2,96,807 | 16.49 | 0.27% | 16.50% | 22.00% | 12,191 | 3,363 | |
| 4,689.50 | 77.80 | 1,78,374 | 9.71 | 0.82% | 27.40% | 15.20% | 17,400 | 2,099 | |
| 2,294.60 | 92.52 | 1,23,980 | 20.45 | 0.04% | 18.30% | 17.80% | 7,823 | 1,332 | |
| 1,200.00 | 28.63 | 1,19,700 | 4.30 | 0.08% | 21.20% | 21.10% | 30,378 | 4,303 | |
| 1,390.20 | 41.44 | 1,16,037 | 2.99 | 0.57% | 11.20% | 13.00% | 33,097 | 2,760 | |
| 1,415.00 | 39.45 | 1,14,312 | 3.23 | 0.92% | 11.60% | 15.50% | 28,139 | 2,855 | |
| Median 7 companies | 1,884.90 | 41.44 | 1,23,980 | 5.07 | 0.57% | 16.50% | 17.80% | 28,139 | 2,855 |
Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company.
Tapetide Score
Data-driven rating, 0–100, as of . How it works →
Overall score
Data confidence 100/100
Category scores
- Quality
- 52
- Average
- Returns, margins, earnings quality 22% weight
- Valuation
- 71
- Strong
- Cheap vs sector & own history 24% weight
- Growth
- 5
- Poor
- Sales & profit trajectory 9% weight
- Financial Health
- 43
- Weak
- Solvency, leverage, coverage 9% weight
- Momentum
- 30
- Poor
- Trend strength, vol-adjusted 12% weight
- Ownership
- 34
- Poor
- FII/DII/promoter flows 24% weight
The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.
Key Insights
Strengths
1- Company's working capital requirements have reduced from 85.1 days to 67.8 days
Weaknesses
1- Dividend payout has been low at 13.2% of profits over last 3 years
Technical Indicators
| Group | Signal | Bearish | Neutral | Bullish |
|---|---|---|---|---|
| Overall | Strong Bullish | 2 | 4 | 13 |
| Oscillators | Bullish | 2 | 4 | 3 |
| Moving Averages | Strong Bullish | 0 | 0 | 10 |
Oscillators
Bullish
Overall
Strong Bullish
Moving Averages
Strong Bullish
Key readings
- RSI (14)
- 68.36
- Neutral
- MACD (12,26,9)
- 36.89
- Bearish
- SMA (50)
- 1,268.95
- Bullish
- SMA (200)
- 1,258.57
- Bullish
As of
Analyst Rating
21 of 36 analysts rate Buy, 8 Hold, 7 Sell.
As of
Growth Rate
From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Sep 2026 against Sep 2025.
Revenue
| 10Y | +8.03% |
|---|---|
| 5Y | +12.09% |
| 3Y | +10.96% |
| 1Y | +3.23% |
| TTM | −3.53% |
Net profit
| 10Y | +6.91% |
|---|---|
| 5Y | +16.33% |
| 3Y | −2.65% |
| 1Y | −27.37% |
| TTM | −51.90% |
Operating cash flow
| 10Y | +5.69% |
|---|---|
| 5Y | +9.71% |
| 3Y | −1.23% |
| 1Y | +22.21% |
| TTM | — |
TTM: Reported once a year, so there is no trailing-twelve-month figure.
Operating margin· change in pp
| 10Y | −3.88 pp |
|---|---|
| 5Y | −1.19 pp |
| 3Y | −7.08 pp |
| 1Y | −7.03 pp |
| TTM | −9.98 pp |
Revenue by year
| Mar 2017 | ₹14,196 Cr |
|---|---|
| Mar 2018 | ₹14,281 Cr |
| Mar 2019 | ₹15,448 Cr |
| Mar 2020 | ₹17,517 Cr |
| Mar 2021 | ₹19,048 Cr |
| Mar 2022 | ₹21,545 Cr |
| Mar 2023 | ₹24,670 Cr |
| Mar 2024 | ₹28,011 Cr |
| Mar 2025 | ₹32,644 Cr |
| Mar 2026 | ₹33,700 Cr |
Net profit by year
| Mar 2017 | ₹1,292 Cr |
|---|---|
| Mar 2018 | ₹947 Cr |
| Mar 2019 | ₹1,950 Cr |
| Mar 2020 | ₹2,026 Cr |
| Mar 2021 | ₹1,952 Cr |
| Mar 2022 | ₹2,182 Cr |
| Mar 2023 | ₹4,507 Cr |
| Mar 2024 | ₹5,578 Cr |
| Mar 2025 | ₹5,725 Cr |
| Mar 2026 | ₹4,158 Cr |
Analyst Forecasts
AI Analysis — Bull vs Bear
Dr Reddy's Laboratories trades at ₹1,377.9 as of 2026-11-16 with a market cap of ₹1,15,010.6 crore and a P/E of 41.07x on trailing earnings. The company has delivered solid long-term sales growth of 8% over 10 years but faces a sharp TTM profit decline of -51%, while maintaining a conservative balance sheet with a debt-to-equity ratio of 0.2.
- Consistent long-term revenue compounder with 10-year sales CAGR of 8% and 5-year sales CAGR of 12%, reflecting durable demand across its generics and specialty portfolio
- Conservative balance sheet with debt-to-equity of just 0.2, providing financial flexibility for acquisitions, R&D investment, or navigating downturns
- Healthy 5-year compounded profit growth of 15%, indicating the business has demonstrated meaningful earnings power over a medium-term horizon
- Working capital efficiency has improved meaningfully, with requirements reducing from 85.1 days to 67.8 days, freeing up cash for productive deployment
- 5-year average ROE of 16% and 3-year average ROE of 16% suggest the company has historically generated attractive returns on shareholder equity
- Stock is trading near its 52-week high of ₹1,414.9, just 2.6% below the peak, indicating sustained investor confidence and positive momentum
- Stock has appreciated roughly 11% over the past 1 year, outperforming its own longer-term CAGR of 8% over 10 years
- TTM profit has declined sharply by -51%, a severe contraction that has compressed EPS to ₹33.55 and elevated the trailing P/E to 41.07x
- TTM sales growth has turned negative at -4%, reversing the positive trend seen over longer periods and raising near-term demand concerns
- 3-year compounded profit growth is -4%, indicating that the earnings weakness is not just a one-quarter anomaly but a multi-year deterioration
- Last year ROE dropped to 11% from the 3-year and 5-year averages of 16%, signalling a meaningful decline in capital efficiency
- Dividend payout has been low at 13.2% of profits over the last 3 years, with a current yield of only 0.58%, offering minimal income return to shareholders
- Price-to-book of 2.97x paired with a declining ROE of 10.87% suggests the market is paying a premium on equity that is currently generating lower returns
- 10-year stock CAGR of only 8% indicates that long-term shareholder wealth creation has been modest relative to the broader market and sectoral peers
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
TL;DR: Dr. Reddy's faces a challenging quarter with a sharp 36% YoY decline in Q2FY27 profit and softening North America revenues. There are no near-term positive catalysts visible in recent news flow. Upcoming investor meets in November may offer management commentary on the recovery path, but the earnings trend is clearly deteriorating and bears watching.
- Q2FY27 PAT drops 36% YoY Oct 23
Net profit fell 36% YoY to ₹9,250 Mn in Q2FY27. Revenue declined 1.5% YoY to ₹86,708 Mn, dragged by lower North America sales.
- Investor meets in Nov 2026 Nov 10
Dr. Reddy's will participate in investor conferences in Mumbai on November 16 and London on November 17-18, 2026.
Quarterly Results
₹ Cr| Particulars | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | 8,698 |
| Expenses | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 | 6,975 |
| Operating Profit | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 | 1,723 |
| OPM % | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% | 20% |
| Other Income | 315 | 216 | 198 | 187 | 308 | 150 | 522 | 290 | 324 | 271 | 480 | 356 | 156 |
| Interest | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 | 125 |
| Depreciation | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 | 527 |
| PBT | 1,913 | 1,826 | 1,602 | 1,877 | 1,911 | 1,870 | 2,000 | 1,905 | 1,739 | 1,543 | 200 | 553 | 1,228 |
| Tax % | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | −11% | 21% | 26% |
| Net Profit | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | 913 |
| EPS (₹) | 17.77 | 16.56 | 15.70 | 16.69 | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 | 11.08 |
| YoY Sales growth | 9 | 7 | 13 | 14 | 16 | 16 | 20 | 11 | 10 | 4 | −12 | −6 | −1 |
Profit & Loss
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 24,670 | 28,011 | 32,644 | 33,700 | 33,097 |
| Expenses | 11,515 | 11,983 | 11,724 | 11,930 | 12,270 | 15,040 | 15,173 | 17,778 | 18,200 | 20,078 | 24,097 | 27,247 | 28,245 |
| Operating Profit | 3,508 | 3,585 | 2,472 | 2,351 | 3,178 | 2,477 | 3,874 | 3,768 | 6,470 | 7,933 | 8,547 | 6,454 | 4,853 |
| OPM % | 23% | 23% | 17% | 16% | 21% | 14% | 20% | 17% | 26% | 28% | 26% | 19% | 15% |
| Other Income | 260 | 295 | 172 | 155 | 381 | 670 | 335 | 555 | 971 | 909 | 1,097 | 1,358 | 1,263 |
| Interest | 108 | 83 | 63 | 79 | 89 | 98 | 97 | 96 | 143 | 171 | 283 | 374 | 450 |
| Depreciation | 760 | 939 | 1,027 | 1,077 | 1,135 | 1,163 | 1,229 | 1,165 | 1,250 | 1,470 | 1,704 | 2,059 | 2,141 |
| PBT | 2,900 | 2,859 | 1,554 | 1,350 | 2,336 | 1,886 | 2,884 | 3,061 | 6,048 | 7,201 | 7,658 | 5,379 | 3,524 |
| Tax % | 19% | 26% | 19% | 32% | 17% | −7% | 32% | 29% | 25% | 23% | 25% | 23% | — |
| Net Profit | 2,336 | 2,131 | 1,292 | 947 | 1,950 | 2,026 | 1,952 | 2,182 | 4,507 | 5,578 | 5,725 | 4,158 | 2,760 |
| EPS (₹) | 27.43 | 24.98 | 15.59 | 11.41 | 23.49 | 24.38 | 23.47 | 26.23 | 54.14 | 66.87 | 67.77 | 50.27 | 33.55 |
| Div. Payout % | 15% | 16% | 26% | 35% | 17% | 21% | 21% | 23% | 15% | 12% | 12% | 16% | — |
| Sales growth | 12 | 4 | −9 | 1 | 8 | 13 | 9 | 13 | 14 | 14 | 17 | 3 | −4 |
Balance Sheet
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 85 | 85 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 83 | 84 | 84 |
| Reserves | 9,768 | 12,484 | 12,179 | 12,489 | 13,941 | 15,516 | 17,558 | 19,129 | 23,203 | 28,171 | 33,466 | 37,808 | 38,724 |
| Borrowings | 4,314 | 3,352 | 4,918 | 5,071 | 3,838 | 2,210 | 3,031 | 3,384 | 1,347 | 2,002 | 4,677 | 7,734 | 7,229 |
| Other Liabilities | 4,290 | 4,408 | 4,474 | 4,706 | 4,557 | 5,414 | 5,915 | 7,149 | 7,576 | 8,523 | 9,797 | 10,951 | 11,596 |
| Total Liabilities | 18,457 | 20,330 | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 56,577 | 57,631 |
| Fixed Assets | 5,377 | 6,563 | 6,931 | 6,968 | 7,191 | 6,850 | 8,206 | 8,122 | 9,219 | 10,426 | 18,226 | 22,063 | 22,173 |
| CWIP | 529 | 772 | 3,324 | 3,470 | 2,934 | 1,535 | 1,565 | 1,293 | 1,030 | 1,419 | 2,466 | 1,460 | 1,207 |
| Investments | 2,248 | 3,833 | 2,110 | 2,298 | 2,587 | 2,678 | 2,212 | 2,616 | 4,986 | 4,930 | 4,051 | 5,285 | 4,502 |
| Other Assets | 10,303 | 9,162 | 9,290 | 9,612 | 9,707 | 12,160 | 14,605 | 17,715 | 16,974 | 22,004 | 23,280 | 27,768 | 29,749 |
| Total Assets | 18,457 | 20,330 | 21,654 | 22,349 | 22,418 | 23,223 | 26,588 | 29,746 | 32,209 | 38,780 | 48,023 | 56,577 | 57,631 |
Cash Flow
₹ Cr| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | 5,888 | 4,543 | 4,643 | 5,674 |
| Investing | −2,370 | −1,610 | −1,890 | −1,483 | −769 | −495 | −2,255 | −2,565 | −4,109 | −4,034 | −5,785 | −6,425 |
| Financing | −433 | −1,700 | −369 | −444 | −2,133 | −2,516 | −30 | −242 | −2,686 | −376 | 1,891 | 829 |
| Net Cash Flow | −280 | −47 | −114 | −124 | −31 | −27 | 1,286 | 3 | −907 | 133 | 749 | 78 |
| Free Cash Flow | 1,009 | 2,065 | 926 | 713 | 2,248 | 2,412 | 2,323 | 1,238 | 4,009 | 1,908 | 1,327 | 2,004 |
| CFO/EBITDA | 88 | 111 | 110 | 88 | 106 | 149 | 107 | 94 | 108 | 83 | 78 | 109 |
Ratios
| Particulars | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 100 | 97 | 98 | 104 | 94 | 105 | 95 | 113 | 107 | 105 | 101 | 110 |
| Inventory Days | 248 | 248 | 282 | 263 | 273 | 230 | 273 | 250 | 232 | 283 | 260 | 228 |
| Days Payable | 84 | 88 | 104 | 121 | 111 | 100 | 109 | 111 | 108 | 116 | 97 | 91 |
| Cash Conversion Cycle | 264 | 257 | 275 | 246 | 256 | 235 | 259 | 252 | 231 | 271 | 264 | 247 |
| Working Capital Days | 26 | 34 | −14 | 39 | 65 | 59 | 57 | 61 | 84 | 118 | 69 | 68 |
| ROCE % | 22% | 19% | 9% | 8% | 13% | 11% | 16% | 14% | 27% | 27% | 23% | 13% |
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Dr Reddys Laboratories insights
70 extracted metrics across FY09–FY27.
Documents
- Q2 FY27 concall · Oct 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026Transcript PPT Recording
- Q1 FY27 concall · Jul 2026Transcript Recording
- Concall · May 2026Transcript PPT
- Concall · May 2026PPT
- 21 Jul 2026
- 30 Mar 2026
- 18 Feb 2026
- 9 Jan 2026
- 27 Dec 2024
- General announcements 10 Nov 2026
- General announcements 5 Nov 2026
- General announcements 4 Nov 2026
Frequently Asked Questions about Dr Reddys Laboratories
What does Dr Reddys Laboratories Ltd do?
Where is Dr Reddys Laboratories Ltd (DRREDDY) listed?
Which sector does Dr Reddys Laboratories Ltd belong to?
What is the market capitalisation of Dr Reddys Laboratories Ltd?
What is the PE ratio of Dr Reddys Laboratories Ltd?
What is the 52-week high and low of Dr Reddys Laboratories Ltd?
Does Dr Reddys Laboratories Ltd pay dividends?
What is the Return on Equity (ROE) of Dr Reddys Laboratories Ltd?
Company Information
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
For AI agents and developers
Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/DRREDDY.md for Dr Reddys Laboratories Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.
Append .md to any Tapetide URL for
the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For
live, structured queries instead of documents, use our Indian stock market MCP server.